Encoded develops a genetic‑medicine platform that uses precise cellular targeting and advanced gene‑regulation techniques to create one‑time gene therapies for neurological disorders. By identifying unique genetic signatures of disease‑relevant cells, the platform delivers therapeutic payloads with high specificity, improving potency and reducing off‑target effects for both monogenic and broader neurodegenerative conditions.
Funding
$135M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFounders
Product
Problem
Neurological disorders cause premature death and lifelong disability, yet existing gene therapies often lack sufficient cell specificity, potency, and durability, limiting their effectiveness for many patients.
Solution
Encoded Therapeutics is building a genetic‑medicine platform that leverages precise cellular targeting and advanced gene regulation to create one‑time gene therapies. By identifying unique genetic signatures of disease‑relevant cell types, the platform can deliver therapeutic payloads selectively to those cells, improving specificity and reducing off‑target effects. The approach incorporates endogenous gene up‑regulation, miRNA knock‑down, and antisense‑mediated unsilencing to modulate disease genes directly. This technology is applied across a pipeline that includes monogenic and more common neurological conditions, aiming to provide long‑lasting, disease‑modifying benefits.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic research groups, seeking advanced gene‑therapy solutions for neurological diseases, and ultimately the patients and families affected by these conditions.
Features
- Cell‑selective targeting using unique genetic profiles to achieve high specificity for desired neuronal subpopulations
- Integrated gene regulation modalities (endogenous up‑regulation, miRNA knock‑down, antisense unsilencing) to modulate disease‑causing genes
- One‑time gene therapy design intended for durable, potentially lifelong therapeutic effect
- Platform‑driven pipeline covering monogenic disorders (e.g., Dravet syndrome, Angelman syndrome) and broader neurodegenerative indications
- Flexible product engine that can be adapted to multiple targets and delivery vectors
- Emphasis on manufacturing scalability to support clinical development and eventual commercialization